The clinical research industry has been reluctant to adopt electronic informed consent (eConsent) for several reasons, not least of which included having to disrupt already stressed and short-staffed work environments to implement new technology. COVID-19 proved to be an inflection point, however, for the industry to continue exploring and implementing digital technologies in earnest.
Fortunately, the eClinical technology industry has benefitted by implementing design techniques and user-centric approaches gleaned from consumer-oriented industries to overcome historic objections.
In this webinar, our experts will talk about the inherent value of eConsent, why the industry has been hesitant to adopt it, factors that are driving the reexamination of this technology solution, and new approaches and features that may help the industry reconsider its value.
Key Learning Objectives:
- Discuss eConsent versus the traditional in-person consultation and paper-based process
- Describe historic objections (from a sponsor and site perspective) to this or any digital technology
- Describe new features that help overcome those obstacles (flexibility for users, improved efficiencies for sponsor/sites/study teams, and more)